Oncotype DX™

Oncotype DX™ is a clinically validated, multi-gene assay that provides a quantitative assessment of the likelihood of distant breast cancer recurrence and also assesses the benefit from chemotherapy. Oncotype DX™ is leading the way to individualised breast cancer treatment by providing valuable, patient-specific information used to assist physicians in optimising treatment plans. The assay — performed using formalin-fixed, paraffin-embedded tumour tissue — analyses the expression of a panel of 21 genes and the results are provided as a Recurrence Score™ (0-100). The gene panel was selected and the Recurrence Score™ calculation was derived through extensive laboratory testing and multiple independent clinical development studies.

Oncotype DX™ is validated for use in breast cancer patients whose disease is newly diagnosed, Stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.

ordering

For information on how to order the Oncotype DX™ test, please contact our Business Development Manager.